Status: Recruiting
ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™
To demonstrate non-inferiority of the Trilogy Transcatheter Heart Valve (THV) System compared with surgical aortic valve replacement (SAVR) for treatment of subjects with clinically significant native aortic regurgitation (AR)
Participants needed: 1,016
Trial details
Biological sex: AllType: InterventionalSponsor: JenaValve Technology, Inc.Updated: Jul 7, 2026Locations: 29
Eligibility criteria
Class I or II indication for AVR according to ACC/AHA or ESC/EACTS guidelines wi... [+4]
Confirmed moderate (2+) or less AR severity by core laboratory evaluation [+51]